Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE
Open Access
- 5 October 2018
- journal article
- research article
- Published by Springer Nature in Forensic Toxicology
- Vol. 37 (1) , 154-163
Abstract
Purpose 5F-CUMYL-PEGACLONE is a recently emerged γ-carbolinone derived synthetic cannabinoid. The present study aimed to identify phase I metabolites to reliably prove consumption of the substance by urine analysis and to differentiate from the uptake of the non-fluorinated analog CUMYL-PEGACLONE. Methods For metabolite characterization, phase I metabolites were analyzed by liquid chromatography–high resolution mass spectrometry after incubation with pooled human liver microsomes. Reliability of the biomarkers was evaluated by analysis of human urine samples (n = 20) by liquid chromatography–triple quadrupole tandem mass spectrometry. Sample preparation included β-glucuronidase treatment followed by liquid-liquid extraction. Results In total, 15 metabolites were detected in vivo and characterized. Metabolic reactions were primarily observed at the γ-carbolinone core and the 5-fluoropentyl chain, and included N-dealkylation, hydroxylation, hydrolytic defluorination, formation of a dihydrodiol, oxidation to the pentanoic acid metabolite and formation of the propionic acid metabolite. Six of these metabolites were identical with phase I metabolites of CUMYL-PEGACLONE, which must be considered for interpretation of analytical findings in urine samples. Conclusions 5F-CUMYL-PEGACLONE was subject to extensive metabolism in humans. The propionic acid metabolite was the most abundant metabolite in all urine samples and should be targeted when maximum sensitivity is needed (e.g., drug abstinence control). However, this metabolite also occurs in the biotransformation of the non-fluorinated analog and is, therefore, not a compound-specific marker. For differentiation, a metabolite hydroxylated at the γ-carbolinone core showed to be the most reliable marker and should be used as an additional target analyte.Keywords
This publication has 20 references indexed in Scilit:
- Approaches, Challenges, and Advances in Metabolism of New Synthetic Cannabinoids and Identification of Optimal Urinary Marker MetabolitesClinical Pharmacology & Therapeutics, 2016
- Phase I metabolism of the highly potent synthetic cannabinoid MDMB‐CHMICA and detection in human urine samplesDrug Testing and Analysis, 2016
- High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human HepatocytesClinical Chemistry, 2016
- Biotransformation of synthetic cannabinoids JWH-018, JWH-073 and AM2201 by Cunninghamella elegansForensic Science International, 2015
- Identification and analytical characteristics of synthetic cannabinoids with an indazole-3-carboxamide structure bearing a N-1-methoxycarbonylalkyl groupAnalytical and Bioanalytical Chemistry, 2015
- Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometryAnalytical and Bioanalytical Chemistry, 2014
- Characteristics of the designer drug and synthetic cannabinoid receptor agonist AM‐2201 regarding its chemistry and metabolismJournal of Mass Spectrometry, 2013
- Identification of a cannabimimetic indole as a designer drug in a herbal productForensic Toxicology, 2009
- ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?Journal of Mass Spectrometry, 2009
- Design, Synthesis and Pharmacology of Cannabimimetic IndolesBioorganic & Medicinal Chemistry Letters, 1994